GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Credit Losses Provision

Spexis AG (XSWX:SPEX) Credit Losses Provision


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Credit Losses Provision?

Credit Losses Provision only applies to banks.


Spexis AG (XSWX:SPEX) Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.